GlassScriptPhysician profile
Onuorah I Umeh
NPI 1972557387
$3,546.39
in general payments reported to CMS, 2019-2025
24 companies · $292 in 2025
The $292 reported for 2025 was more than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $850 · 2020: $570 · 2021: $582 · 2022: $568 · 2023: $296 · 2024: $388 · 2025: $292.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $968 · Education: $8.56.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $967.69 |
| Education | $8.56 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $754.65 | 2019-2021 | |
| Novo Nordisk INC | $485.23 | 2019-2025 | Rybelsus, Ozempic |
| Janssen Pharmaceuticals, INC | $442.39 | 2019-2022 | |
| Lilly USA, LLC | $325.35 | 2021-2025 | Mounjaro, Zepbound |
| Boehringer Ingelheim Pharmaceuticals, INC. | $153.97 | 2019-2025 | Jardiance, Tradjenta |
| Merck Sharp & Dohme LLC | $153.67 | 2019-2021 | |
| Amgen INC. | $150.32 | 2023-2025 | Otezla, Repatha, Otezla |
| Novartis Pharmaceuticals Corporation | $145.09 | 2019-2024 | |
| Xeris Pharmaceuticals, INC. | $141.15 | 2021-2023 | Gvoke Hypopen |
| Abbott Laboratories | $131.95 | 2021-2024 | Freestyle Libre 3 |
| Glaxosmithkline, LLC. | $124.14 | 2019-2025 | Arexvy, Shingrix |
| Amarin Pharma, INC. | $101.22 | 2019-2022 | |
| Pfizer INC. | $82.11 | 2022-2024 | |
| Exact Sciences Corporation | $81.72 | 2024 | Cologuard Collection Kit |
| Kowa Pharmaceuticals America, INC. | $61.80 | 2023-2025 | Zoryve, Seglentis |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Global Blood Therapeutics, INC. | $44.03 | 2021-2022 | |
| Hikma Pharmaceuticals USA | $39.91 | 2019-2020 | |
| Gilead Sciences, INC. | $27.53 | 2025 | Yeztugo |
| Insulet Corporation | $21.39 | 2025 | Omnipod |
| E.R. Squibb & Sons, L.L.C. | $20.53 | 2024 | Camzyos |
| Sanofi-Aventis U.S. LLC | $18.69 | 2019 | |
| Phadia US INC. | $17.24 | 2021 | |
| Medtronic, INC. | $13.75 | 2022 | |
| Travere Therapeutics, INC. | $8.56 | 2023 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Onuorah Umeh listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.